SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

 

For the month of    November    2016
Commission File Number        001-36458    

 

 

Neovasc Inc.

(Translation of registrant’s name into English)

 

Suite 5138 – 13562 Maycrest Way

Richmond, British Columbia, Canada V6V 2J7

  

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

  Form 20-F        Form 40-F    X  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):           

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           


 

 

 
 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

 

Document    
     
1  

News Release dated November 23, 2016 - Neovasc Announces Dismissal of Class Action Lawsuit

 

 

 
 

 

Document 1

 

Neovasc Announces Dismissal of Class Action Lawsuit

NASDAQ: NVCN
TSX: NVC

VANCOUVER, Nov. 23, 2016 /CNW/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ: NVCN) (TSX: NVC) announced today that the United States District Court for the District of Massachusetts granted the Company's motion to dismiss with prejudice in the case of Grobler v. Neovasc Inc, et al., Civil Action No. 16-11038-RGS, a putative securities class action that was filed on June 6, 2016 against the Company and certain of the Company's officers. 

The Court ruled in favor of the Company and its officers on all claims and ordered the entire case closed.  The Company is not aware as to whether, and presently cannot foresee whether, the plaintiff will appeal the dismissal of his claims or will file any post-dismissal motions.

About Neovasc Inc.  
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products in development include the Tiara™, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, including statements regarding any future developments in the class action litigation, including any potential appeals and post-dismissal motions.  The words "cannot foresee" and "will" are intended to identify these forward-looking statements.  Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances.  Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, potential changes in circumstances relating to litigation involving the Company, whether as a result of unforeseen circumstances or otherwise; and the conduct or possible outcomes of any actual or threatened legal proceedings, including any post-dismissal motions or appeals, which are inherently uncertain. Risk factors concerning the class action litigation and others relating to the Company were previously discussed in greater detail in the "Risk Factors" section of the Company's Annual Information Form, which is included in its Annual Report on Form 40-F (copies of which filings may be obtained at www.sedar.com or www.sec.gov).  These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements.  The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Neovasc Inc.

 

%CIK: 0001399708

For further information: Investor Relations: Neovasc Inc., Chris Clark, 604 248-4138, cclark@neovasc.com

CO: Neovasc Inc.

CNW 08:14e 23-NOV-16

  

 

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

  Neovasc Inc.
  (Registrant)
   
Date:             November 23, 2016   By:    /s/ Chris Clark
  Name:    Chris Clark
  Title: Chief Financial Officer

Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Neovasc Charts.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Neovasc Charts.